by Paul McIntosh | Mar 30, 2021 | 2021, Blog Post
By Grant Ellis, Director, NovaBiotics Ltd A number of commentators are now saying that as a result of the vaccines, COVID 19 will be akin to flu – something that comes around every year but for most of us nothing more than an inconvenience and only severely...
by Paul McIntosh | Feb 26, 2021 | 2021, Press Releases
Aberdeen, UK – 26th February 2021 – NovaBiotics Ltd, the clinical-stage anti-infectives biotechnology company, today announced that it has entered into a licensing agreement with an undisclosed partner to commercialise its NP213 peptide in a topical (brush/paint-on)...
by Paul McIntosh | Dec 31, 2020 | 2020, Blog Post
By Grant Ellis, Director NovaBiotics Ltd Back in October I quoted Sir Patrick Vallance, the government’s Chief Scientific Adviser saying that no vaccine for Covid was likely before the spring of 2021. We all now know that there are two vaccines that have been...
by Paul McIntosh | Dec 29, 2020 | 2020, Press Releases
NovaBiotics are delighted to announce that our CARE CF 1 phase 2b clinical trial data for oral Lynovex in infectious pulmonary exacerbations of cystic fibrosis is published today in PLOS ONE. Our findings further support the potential of Lynovex® as game-changer in CF...
by Paul McIntosh | Dec 28, 2020 | 2020, Press Releases, Uncategorized
NovaBiotics featured in an article published in the Mail on Sunday on 27 December 2020 entitled “British scientists are engineering superbug-beating medications to fight off killer infections including MRSA.” See the full article by clicking Mail on Sunday Article 27...
by Paul McIntosh | Nov 18, 2020 | 2020, Blog Post
To mark World Antimicrobial Awareness Week, Deborah O’Neil tells pharmaphorum why 2021 might be the year anti-infective drugs finally demonstrate their economic value. You can access full article here Pharmaphorum Article 18 Nov 2020
Contact Us
Technology
Therapeutic Focus
News and Events
Recent Comments